Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Breast cancer presentation1


Published on

Breast cancer presentation 1

Dr.Ofail Nadeem Feb. 2014

Published in: Education
  • Be the first to comment

Breast cancer presentation1

  1. 1. Breast cancer MANAGEMENT PPTX. BY DR.OFAIL N.K. FEB.2014
  2. 2. • Genetic councelling in breast cancer: • 1-age<40 with personal Hx of BC • 2- strong FAMILY Hx of BC at early age • 3- women<50 with ashknasi-Jewish ancestry or polish ancestry. • 4- Relatives with known Hx of BRCA1,BRCA2 gene mut. • 5- Hx of male BC • 6- Pt. with 2 primary cancers. • 7- Pt. with fallopian tube cancer. • Staging: • Stage I-------T1N0, T1Nmic • Stage II------T1N1, T2N0, T2N1, T3N0 • Stage III------ All (N2,N3)M0, T3N1, All T4 M0 • Stage IV------ M1 N1mic=>0.2mm<2mm pN1=1-3 LN pN2=4-9 LN pN3=>=10 LN
  3. 3. • Px: • Axillary LN status, tumor size, grade , age, biological subtype as defined by mol. Markers. • ER,PR are growth regulating nuclear transcriptase factors • Biological subtypes= Luminal = ER+Pr+ • 1- Luminal A=Er+Pr+Her2 – • 2- Luminal B= ER+PR+Her2+ • 3- HER2= ER-PR-Her2+ • 4- Triple –ve(basal subtype) ER-PR-HER2-
  4. 4. • Early stage BC Treatment : • For BCT combination of Sx, Rt, Ct. • Sx: • Lumpectomy is appropriate for DCIS and stage I , II invasive ductal or lobular ca. • Mastectomy is indicated in all pt. who r not suitable for BCT. • For invasive cancers SNB +- axillary dissection for the +ve node is routinely accomplished. • Loco-regional recurrence after lumpectomy alone without adjuvant Rx is 40% for invasive dis. • Role of additional axillary dissection for +ve SNB by IHC is controversial. • RT: • 1- as adj. after lumpectomy for DCIS & early stage invasive dis. • 2- as adj. after mastectomy for high risk locally advanced dis. Including inflamm. BC. • 3- as palliative tool for metastatic dis. •
  5. 5. • Technique: • WBI: EBRT delivered via 3DCRT or IMRT for DCIS and early stage invasive dis. • Selected nodal irradiation to SC, axilla, IMN done wn there is pathologically documented dis. • PBI– using Brachy. Or EBRT is done in selected cases. • For locally advanced dis. Irradiation to chest wall + sc+ axilla+ breast bed+- IMN is planned. • CT/Hormonal: • 1- Adj. hormonal as chemo prevention in DCIS • 2- Adj. hormonal used for low and intermediate RISK early dis. • 3- Adj. CT for intermediate and high RISK early dis. And advanced dis. • 4- Neo-adj. For locally advanced (for downstaging to allow BCT) and Inflamm. BC. • First line active hormonal= Tam, arimidex, raloxifen • First line chemo= anthracycline and taxane based multi-agent CT. • First line Biologic Rx = Herceptin combined with multi-agent CT. • Adj. CT is given prior to RT.
  6. 6. • 20% of all BC diagnosed as insitu. And generally made via mammography. • LCIS is managed by active survillence but the option for bilateral mastectomy is based upon individualized risk assessment under special circumstances e.g: BRCA1,2 mut. Or strong family Hx. • Local Rx for LCIS at Dx is not indicated only risk reduction strategies with chemoprevention (Tam or Ral). • Adj. RT is indicated in all subgroups of DCIS after lumpectomy. • A recent single arm observational trial has indicated observation after lumpectomy , this option is used only in a very selected group of elderly pt with DCIS. • In DCIS Van-Nuys prognostic index ( I ,II ,III ) is used based on : • size (<1.5mm, 1.6mm-4mm,>4mm) • Grade( No necrosis, necrosis, grade III) • Margin( >10mm, 1-9 mm, <1mm) • Age( >60y, 40y-60y, <40y) • If total score 4-6  may consider lumpectomy followed by active survillence.
  7. 7. • Adj. hormones in DCIS  Tam reduce recurrence of DCIS but it cannot replace RT in risk reduction for local recurrence since recurrence rate was 6% after RT as compared with 14% without. • Summary: • LCIS--Routine risk background observation +- Tam. active follow up • • - BRCA1,2 background bilateral mastectomies +- reconstruction +- Tam.-active follow up. • DCIS - Localised lumpectomy  Margin >2mm observe +- Tam. For low G. Small lesion premenopausal. •  Margin <2mm RT +- Tam. • - diffused(microcalcif.) mastectomy with reconstruction active FU. • For insitu dis with lumpectomy or mastectomy SNB is generally not indicated. Only in case of
  8. 8. Rx of early stage invasive BC: (I-IIa) BCT( lumpectomy+RT). Standard is WBI+- regional L.N. as defined by the extent of the disease. Relative C/I for BCT: 1- Gross multicentric 2-Pg. 3- prior irradiation. 4- scleroderma If mastectomy done in early disease RT usually is not indicated . PBI: both WBI & PBI have equivalent local control and survival amomg appropriately selected Pt.
  9. 9. Summary for early BC radiation treatment: Completed lumpectomy risk stratification (histology(DCIS),invasive, N0-N1, menopausal status<50, Hormonal status, intent to receive CT.  EarlyBC ( low risk, moderate risk, high risk)  WBI 50-50.4 Gy In 25-28 f to entire breast followed by boost to lumpectomy site to total 60-66.4 Gy.  PBI  1- accelerated 34Gy in 3.4 Gy/f Twice a day over 5 days using interstitial BT.  2- 38.5 Gy in 3.85 Gy/f Twice for 5 days using 3DCRT Use of risk stratification significantly reduce RR ; however in selected pt ( elderly, early stage, severe morbidities, limited life span who have low risk of failure may attempt lumpectomy alone.
  10. 10. Early stage invasive ca. localizedlumpectomy (-ve margin >2mm)+SNBWBI/PBIobserve+- TAM **If recommended CT it is always delivered before RT diffusedmastectomy+SNBCTRT for intermediate & high risk observe+- TAM To be continued next presentation……………………..